• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Morpholines

Introduction to [(3R)-4-methylmorpholin-3-yl]methanol (CAS No. 1620510-51-1)

[(3R)-4-methylmorpholin-3-yl]methanol, with the CAS number 1620510-51-1, is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is a derivative of morpholine, a six-membered heterocyclic amine, and features a unique stereochemistry that imparts specific biological activities and properties. The compound's structure includes a 4-methyl substitution on the morpholine ring and a hydroxymethyl group attached to the chiral center at the 3-position.

The chirality of [(3R)-4-methylmorpholin-3-yl]methanol is crucial for its biological activity, as enantiomers can exhibit different pharmacological profiles. The (3R) configuration specifically has been studied for its potential applications in drug development, particularly in the context of enzyme inhibitors and receptor modulators. Recent research has highlighted the importance of chiral compounds in enhancing the selectivity and efficacy of therapeutic agents.

In terms of synthesis, [(3R)-4-methylmorpholin-3-yl]methanol can be prepared through various methodologies, including asymmetric synthesis and chiral resolution techniques. One common approach involves the use of chiral catalysts or auxiliaries to achieve high enantiomeric excess (ee) in the final product. This ensures that the desired (3R) enantiomer is obtained with high purity, which is essential for pharmaceutical applications.

The physical properties of [(3R)-4-methylmorpholin-3-yl]methanol include its solubility in common organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO). Its melting point and boiling point are also important parameters for handling and storage. The compound's stability under various conditions, such as temperature and pH, has been studied to ensure its suitability for long-term storage and use in formulations.

In biological studies, [(3R)-4-methylmorpholin-3-yl]methanol has shown promising activity as an inhibitor of specific enzymes involved in metabolic pathways. For instance, it has been investigated for its potential to inhibit enzymes related to cancer metabolism, such as lactate dehydrogenase (LDH) and pyruvate kinase M2 (PKM2). These enzymes play critical roles in tumor growth and progression, making them attractive targets for therapeutic intervention.

Additionally, [(3R)-4-methylmorpholin-3-yl]methanol has been explored for its ability to modulate receptors involved in neurological disorders. Research has indicated that it can interact with specific receptors in the central nervous system (CNS), potentially offering new avenues for treating conditions such as Alzheimer's disease and Parkinson's disease. The compound's ability to cross the blood-brain barrier (BBB) is a key factor in its potential therapeutic applications.

The pharmacokinetic properties of [(3R)-4-methylmorpholin-3-yl]methanol have also been studied to understand its behavior in vivo. Factors such as absorption, distribution, metabolism, and excretion (ADME) are crucial for evaluating its suitability as a drug candidate. Preclinical studies have shown that the compound exhibits favorable pharmacokinetic profiles, with good oral bioavailability and low toxicity.

In clinical trials, early-phase studies have been conducted to assess the safety and efficacy of [(3R)-4-methylmorpholin-3-yl]methanol. These trials have provided valuable insights into its potential therapeutic effects and have identified areas for further optimization. Ongoing research aims to refine the compound's structure to enhance its potency and selectivity while minimizing side effects.

The market potential of [(3R)-4-methylmorpholin-3-yl]methanol is significant given its diverse applications in drug development. As pharmaceutical companies continue to invest in research and development, compounds like this one are expected to play a crucial role in advancing therapeutic options for various diseases. The growing demand for targeted therapies with improved safety profiles further underscores the importance of compounds like [(3R)-4-methylmorpholin-3-yl]methanol.

In conclusion, [(3R)-4-methylmorpholin-3-yl]methanol (CAS No. 1620510-51-1) represents a promising compound with potential applications in medicinal chemistry and pharmaceutical research. Its unique stereochemistry, favorable biological activity, and promising pharmacokinetic properties make it an attractive candidate for further development. Continued research into this compound is expected to yield valuable insights and potentially lead to new therapeutic breakthroughs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)